Muscle mass in lung cancer patients may play a decisive role in determining the success of immunotherapy. A new study indicates that patients with advanced non-small cell lung cancer (NSCLC) who suffer from sarcopenia—the progressive loss of skeletal muscle mass and strength—face a 2.63-times higher risk of cancer progression or worsening compared to those with adequate muscle mass. Non-small cell lung cancer is the most prevalent form of the disease, accounting for roughly 85% of all lung cancer cases, and "advanced" refers to stages 3 and 4, where surgical removal is no longer a viable option.
A joint research team announced on the 26th that immunotherapy outcomes were significantly compromised in advanced NSCLC patients with muscle wasting. The collaborative study was led by Professor Choi Ju-hwan and Professor Lee Seung-ryong of the Division of Pulmonary and Allergy Medicine at Korea University Guro Hospital, alongside Professor Park Ji-eun and Professor Shin Young-gi of the College of Pharmacy at Seoul National University. The findings were published in the March 2026 issue of the peer-reviewed journal Scientific Reports.
Precise Muscle Tracking Reveals a Severe Prognosis
The researchers evaluated 74 patients with advanced non-small cell lung cancer who were receiving immunotherapy as their first-line treatment. To diagnose sarcopenia with high accuracy, the team utilized dual-energy X-ray absorptiometry (DXA) to measure appendicular skeletal muscle mass. Unlike previous studies that relied on a single waist CT cross-section, DXA differentiates bone, fat, and lean muscle tissue to evaluate whole-body muscle mass simultaneously. Under established Korean diagnostic criteria, sarcopenia is defined as a skeletal muscle mass index of less than 6.43 kg per height in meters squared (kg/m2) for men and less than 5.34 kg/m2 for women.
The clinical data revealed an alarming trend: out of the 74 monitored patients, 58 (78.4%) already presented with sarcopenia before treatment began. For these patients, the median time before the cancer began to progress or worsen was just 74 days—not even half the 172-day progression-free survival seen in patients without muscle wasting. This represented a 2.63-fold increase in the risk of disease progression. Even after adjusting for confounding clinical variables such as age, biological sex, and specific treatment regimens, sarcopenia remained a standalone, independent predictor of poor patient prognosis.
The Biological Breakdown of the Immune System
The research team uncovered a critical biological mechanism explaining why muscle loss paralyzes modern cancer drugs. As skeletal muscle mass declines, the body experiences a sharp rise in systemic inflammatory signals, specifically cytokines like interleukin-6 (IL-6). This chronic inflammatory state effectively depletes and exhausts CD8+ T cells—the primary killer immune cells responsible for targeting and destroying malignant cancer cells. On the surface of these weakened immune cells, an inhibitory checkpoint protein called TIGIT increases. Once TIGIT expression rises, immunotherapy drugs are blocked from properly activating the immune system against the tumor.
The study established that lower muscle mass directly correlates with a higher frequency of these dysfunctional, exhausted immune cells. Among patients who exhibited both sarcopenia and high TIGIT expression, the risk of rapid cancer progression surged to 3.5 times higher, marking the absolute worst prognosis within the entire cohort.
Currently, immunotherapy stands as the premier first-line treatment for advanced non-small cell lung cancer, yet clinical responses vary widely from person to person. Historically, the expression of the PD-L1 protein has been the sole validated predictive marker used by oncologists, though experts have long noted its limitations. This new research suggests that assessing muscle status alongside blood immune markers like TIGIT and inflammatory cytokines could allow physicians to accurately estimate treatment efficacy before a single dose is administered. While the small sample size of 74 patients means larger validation trials are necessary, the clinical implications are profound.
Professor Choi Ju-hwan noted, “We confirmed that sarcopenia can be an important indicator for predicting immunotherapy prognosis in patients with advanced non-small cell lung cancer. Assessing sarcopenia together with blood biomarkers will help establish personalized treatment strategies for each patient.”
Skeletal muscle is far more than an indicator of physical stamina; it serves as a regulatory organ shaping the operating environment of the entire human immune system. For individuals preparing for or currently undergoing advanced lung cancer therapy, checking muscle status with a physician and potentially combining targeted protein supplementation with structured resistance training could prove to be a vital component of a comprehensive care strategy.
